April 23, 2024

Gene Delivery Seminar – From Blueprint to Biology: Designing Transient mRNA Therapeutics for Next‑Wave Medicine.

Gene Delivery Seminar – From Blueprint to Biology: Designing Transient mRNA Therapeutics for Next‑Wave Medicine.
Go back

mRNA is moving beyond vaccines, but where is it going next?
Join VectorBuilder’s next Gene Delivery Seminar to learn how advances in mRNA design are enabling precise, transient protein expression across diverse disease areas.

Dr. Francis Enane from Indiana Biosciences will highlight advances in mRNA design and stability, including optimized UTRs, nucleoside modifications, and emerging modalities like sa-RNA and circ-RNA. You’ll also learn how new LNP technologies are unlocking tissue-targeted delivery!

Date: Thursday, April 23rd, 2026
Time: 11:00 AM EST | 3:00 PM GMT

Register here!

https://us06web.zoom.us/webinar/register/7017576877969/WN_WwxvBGUQT6SPZepMPFv8YQ

register now

Our latest News

discover more
Interdisciplinary Care for Elderly Trauma Patients: Heidelberg University Hospital’s Center for Geriatric Trauma Receives Certification

Interdisciplinary Care for Elderly Trauma Patients: Heidelberg University Hospital’s Center for Geriatric Trauma Receives Certification

The German Society for Trauma Surgery has jointly certified the Department of Trauma and Reconstructive Surgery at Heidelberg University Hospital (UKHD) and Agaplesion Bethanien Hospital Heidelberg as a Geriatric Trauma Center. The certification recognizes the outstanding care provided to elderly trauma patients at UKHD and underscores the great importance of interdisciplinary geriatric medicine. Full text […]

read more
Tony Hyman starts as EMBL Director General

Tony Hyman starts as EMBL Director General

Former EMBL group leader returns to lead the organisation’s six sites at a time of change and opportunity in life sciences EMBL welcomes its new Director General, Tony Hyman, who will take up the mandate of leading EMBL’s six sites as the organisation enters its next phase. Hyman succeeds Interim Director Ewan Birney, who assumed leadership […]

read more
New Mouse Model: Rhabdomyosarcoma GEMM

New Mouse Model: Rhabdomyosarcoma GEMM

We are very proud to be a part of a joint, international effort to develop a genetically engineered mouse model (GEMM) for the understudied pediatric cancer, alveolar rhabdomyosarcoma (aRMS). This model, which has been deposited at JAX (strain 041178), will accelerate the development of living-saving therapies for children with aRMS. This model was developed as a […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp